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Abstract
Neuroinflammation and blood brain barrier (BBB) dysfunction have been implicated in the pathogenesis of Parkinson’s
disease (PD). The neuropeptide substance P (SP) is an important mediator of both neuroinflammation and BBB dysfunction
through its NK1 receptor in a process known as neurogenic inflammation. Increased SP content has previously been
reported following 6-OHDA treatment in vitro, with the levels of SP correlating with cell death. The present study used an in
vivo 6-OHDA lesion model to determine if dopaminergic degeneration was associated with increased SP in the substantia
nigra and whether this degeneration could be prevented by using a SP, NK1 receptor antagonist. Unilateral, intrastriatal 6-
OHDA lesions were induced and SP (10 mg/2 mL) or the NK1 receptor antagonists, N-acetyl-L-tryptophan (2 mL at 50 nM) or
L-333,060 (2 mL at 100 nM), administered immediately after the neurotoxin. Nigral SP content was then determined using
immunohistochemical and ELISA methods, neuroinflammation and barrier integrity was assessed using Iba-1, ED-1, GFAP
and albumin immunohistochemistry, while dopaminergic cell loss was assessed with tyrosine hydroxylase immunohisto-
chemistry. Motor function in all animals was assessed using the rotarod task. Intrastriatal 6-OHDA lesioning produced an
early and sustained increase in ipsilateral nigral SP content, along with a breakdown of the BBB and activation of microglia
and astrocytes. Further exacerbation of SP levels accelerated disease progression, whereas NK1 receptor antagonist
treatment protected dopaminergic neurons, preserved barrier integrity, reduced neuroinflammation and significantly
improved motor function. We propose that neurogenic inflammation contributes to dopaminergic degeneration in early
experimental PD and demonstrate that an NK1 receptor antagonist may represent a novel neuroprotective therapy.
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Introduction
Parkinson’s disease (PD) is the second most common neurodegen-
erative disorder affecting approximately 1% of the world’s population
over the age of 65 [1]. It is characterized by a progressive loss of
dopaminergic neurons from the substantia nigra (SN), an integral
part of the basal ganglia (BG). The BG is a group of nuclei that is
primarily involved in the smooth execution of movement, and whose
complex function requires that its two main signalling pathways be
balanced. These pathways are kept in balance by the release of
dopamine (DA) from dopaminergic neurons projecting from the SN
to the striatum (caudaute nucleus and putamen). For proper function
of the BG, a basal level of striatal DA release is required; therefore in
PD,alossofstriatalDAcausesmotorsymptomssuchasbradykinesia,
akinesia, rigidity and postural instability. Accordingly, current
treatment for PD involves increasing striatal DA levels by either
direct replacement with L-DOPA, by administering DA agonists or
by reducing DA metabolism. However, these only provide
symptomatic relief and do not target the cause of the dopaminergic
cell loss. Moreover, while L-DOPA is highly effective in reducing
motor symptoms for the first 5 to 10 years of use, continued use
produces motor complications like dyskinesia and motor fluctuations
[2]. Importantly, the progressive nature of cell loss in PD provides a
window of opportunity in which a neuroprotective therapy could be
administered to slow down or halt the progression of the disease.
Unfortunately no known therapy exists to date.
Inflammatory processes and blood brain barrier (BBB) dysfunc-
tion have been associated with dopaminergic cell loss in PD.
Activation of CNS immune cells such as microglia is observed in
all animal models of PD, and in the SN of PD patients both on
PET scans and at post-mortem [3,4,5]. Activated microglia
damage cells by releasing pro-inflammatory cytokines, reactive
oxygen species (ROS), nitric oxide (NO) and excitatory factors. An
astrocytic response has also been observed in animal models of PD
[3,6], although the involvement of these cells in PD pathogenesis
still remains controversial [7]. The loss of BBB integrity reported
in PD is thought to also contribute to the progression of the disease
[8,9]. The barrier of the SN is known to be weaker than in other
brain regions and therefore can be easily disrupted [10].
Moreover, dopaminergic neurons seem particularly vulnerable to
BBB dysfunction, since induction of barrier breakdown leads to
increased expression of apoptotic markers in DA neurons but not
in hippocampal neurons [11].
An important mediator of both inflammation and increased
BBB permeability in the CNS is the neuropeptide, substance P
(SP). SP belongs to the tachykinin family, is widely found
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preferentially binds to the NK1 tachykinin receptor, which like SP,
is broadly distributed throughout the body. Accordingly, SP is
involved in a diverse range of functions including smooth muscle
contraction, transmission of sensory information, and nociception,
amongst others (reviewed by [12]). SP is found in particularly high
levels in the SN. Here, SP binds to NK1 receptors expressed on
dopaminergic neurons, where internalisation of the SP/NK1
complex causes excitation and the release of DA into the striatum
[13]. However, DA can also potentiate the release of SP within the
nigra by binding to its D1 receptor located on striatal SP-
containing medium spiny projection neurons [14]. Thus, SP and
DA regulation is via a positive feedback mechanism.
Recently, 6-OHDA treatment of dopaminergic neurons in vitro
produced an early and sustained increase in SP content, which
significantly correlated with lactate dehydrogenase expression, a
marker of cell death [15], suggesting that SP may play a role in
dopaminergic cell. In the current study, we investigated whether
SP may also be increased in vivo following induction of intrastriatal
6-OHDA lesions, a model of early PD, thereby initiating DA cell
death by facilitating inflammation and BBB dysfunction.
Results
Intrastriatal injections of 6-OHDA resulted in a progressive loss
of TH positive neurons in the ipsilateral SN that was not apparent
until day 7 post-lesion and was significant by day 14 (p,0.001;
Figure 1A). By day 21, vehicle treated animals demonstrated
further loss of these neurons. This loss was significantly
exacerbated when SP was administered immediately after the 6-
OHDA (p,0.01). Conversely, treatment with the NK1 receptor
antagonists, NAT and L-733, 060, protected TH neurons, with
these animals demonstrating a 28.565.8% and a 28.164.1% loss
of neurons, respectively, compared to the 40.963.1% loss reported
in vehicle treated animals.
The loss of ipsilateral TH positive nigral neurons produced a
significant motor deficit as assessed by the rotarod task (Figure 1B).
In contrast to sham animals who had normal motor function and
could complete the 2 min task, vehicle treated animals were
unable to learn the task and overall recorded a mean of
78.960.9 secs. SP treated animals displayed greater motor deficits
as they performed only 69.861.1 secs on the rotarod task, whereas
both NAT and L-733,060 treated animals performed significantly
better than vehicle treated animals throughout the assessment
period (p,0.05).
To determine the mechanism by which NK1 antagonism
protected DA neurons and improved motor function, SP content,
BBB integrity and neuroinflammation was assessed. Intrastriatal 6-
OHDA lesions produced an early and sustained increased in SP
content in the ipsilateral SN compared to the contralateral SN
(Figure 2A–C). Vehicle treated animals had greater SP content,
whereas animals treated with SP or an NK1 antagonist had
comparable SP content to shams. SP content was also measured at
day 3 and 7 using an ELISA assay (Figure 2D). Again, an increase
in SP content was recorded in the ipsilateral striatum and SN, with
a greater rise seen in the striatum at day 3 and within the SN at
day 7. Thus the day at which SP was maximal differed in each
technique. This is likely due to ELISA assessing the entire SN and
some of the surrounding tissue compared to color deconvolution,
which primarily included the pars compacta region of the SN.
6-OHDA intrastriatal lesions resulted in BBB breakdown and
obvious albumin immunoreactivity in the ipsilateral nigra by day 7
post-lesion. Loss of barrier integrity was still apparent at day 21 as
vehicle treated animals had marked albumin immunoreactivity
(Figure 3). SP treated animals also demonstrated BBB dysfunction,
however treatment with an NK1 antagonist preserved barrier
integrity with both NAT and L-733,060 treated animals
resembling sham animals.
Intrastriatal 6-OHDA lesions resulted in marked neuroinflam-
mation (Figure 4 and 5). A small increase in Iba-1 positive reactive
microglia was seen by day 3, and was maximal by day 14 at which
point a significant increase in Iba-1 immunoreactive microglia was
detected (p,0.01). Although the presence of ED-1 positive
microglia was also maximal at day 14, the appearance of these
cells was not seen until day 7 post-lesion. Vehicle treated animals
had a significant increase in the number of both Iba-1 and ED-1
positive microglia compared to sham animals (p,0.01). SP
treatment exacerbated the microglial response as these animals
had a greater number of both Iba-1 and ED-1 immunoreactive
microglia than vehicle treated animals, although this increase was
not significant. Conversely, both NAT and a L-733,060 treated
animals had an approximate 10% decrease in ED-1 immunore-
active microglia compared to vehicle treated animals. Despite this,
Figure 1. The effects of SP and NK1 antagonist treatment on
nigral neuronal cell loss and motor function in rats following 6-
OHDA intrastriatal lesions. (A) ipsilateral nigral dopaminergic
neuronal loss as assessed by TH immunoreactivty; (B) motor function
as assessed by an accelerating rotarod task.
doi:10.1371/journal.pone.0034138.g001
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positive microglia.
The presence of GFAP positive reactive astrocytes was similar to
microglia. Maximal numbers of reactive astrocytes were recorded
on day 14 post-lesion, with a highly significant increase still
apparent in vehicle treated animals compared to sham animals
(p,0.001). However, both SP and NK1 antagonist treatment
resulted in a small decline in reactive astrocytes compared to
vehicle treated animals, although a significantly greater number
was still apparent compared to shams.
Discussion
In the current study, we demonstrate that intrastriatal 6-OHDA
lesions result in elevated SP production within the ipsilateral SN
that remained above sham levels for 21 days. The increased SP
levels were associated with increased BBB permeability, microglial
and astrocyte activation, increased dopaminergic cell death and
profound motor deficits. Moreover, treatment with additional SP
at the time of 6-OHDA administration accelerated the progression
of the disease, with animals displaying profound motor deficits and
exacerbated dopaminergic cell death. In contrast, blocking the
effects of SP with administration of an NK1 antagonist preserved
barrier integrity, reduced inflammatory processes, attenuated 6-
OHDA induced cell death and resulted in a significant
improvement in motor function. To the best of our knowledge,
this is the first demonstration that increased SP may play a critical
role in early dopaminergic degeneration.
Although a potential role for SP in PD has been previously
suggested, unlike in the current study, this was on the basis of
decreased SP content and NK1 receptors within the BG in both
clinical [16,17,18,19,20,21] and experimental models of PD
[22,23]. These reports of SP decline were in post-mortem PD
tissue and in models that replicate the late stages of the disease. It
is likely that the observed loss of SP under these conditions is a
secondary effect of dopaminergic degeneration, due to the
interruption to the positive feedback regulation between SP and
DA. Indeed, a 90% decrease in striatal DA has reportedly been
required to deplete SP content within the SN [19]. In this study,
nigral SP content was only decreased in the SP treated animals,
which had significantly greater dopaminergic neuronal loss than
any other group.
There are several possible mechanisms to account for the
increase in SP seen in this study. During early dopaminergic
degeneration, DA production is upregulated from surviving
neurons in an attempt to attenuate the loss of striatal DA [24].
As mentioned, in the nigrostriatal pathway of the BG, SP and DA
production are modulated by a positive feedback mechanism,
whereby each neurotransmitter can potentiate the release of the
other. Thus an increase in DA turnover may facilitate a localized
increase in nigral SP. Another possible source of SP is other BG
nuclei such as the globus pallidus (GP), which is also involved in
Figure 2. Changes in substance P content following intrastriatal 6-OHDA lesions. Substance P content in the ipsilateral SN (A) compared to
the contralateral SN (B) is increased according to color deconvolution (C) and by an ELISA method (D). Arrows denote rise in SP. Bar=300 mm.
doi:10.1371/journal.pone.0034138.g002
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projections from the internal segment of the GP to the SN [25].
Furthermore, the increase in nigral reactive astrocytes seen
following intrastriatal 6-OHDA lesions can account for increased
SP, as they are also known to produce SP [26].
This increase in SP is significant given that SP induces
neurogenic inflammation, a neurally elicited inflammatory re-
sponse caused by injury or infection, and involving the release of
calcitonin-gene related peptide (CGRP) and SP from primary
sensory nerve fibers surrounding blood vessels [27]. CGRP, a
potent vasodilator, increases blood flow whereas SP, by binding to
NK1 receptors on perivascular tissue, induces plasma extravasa-
tion, BBB breakdown and often genesis of edema [28]. Although
this process has been well described in peripheral nervous system
tissue, it has only recently been described following injury to the
brain [27,28,29,30]. Recently, a loss of BBB integrity has been
implicated in the progression of PD [8,9,11].
SP induced breakdown of the BBB, as seen with albumin
immunoreactivity, was noted in this study, with treatment with an
NK1 antagonist preserving barrier integrity. Even a small
breakdown in the BBB can be harmful to neurons by permitting
an influx of peripheral immune cells, such as T-lymphocytes,
blood borne macrophages and neutrophils into the brain.
Peripheral immune cells also secrete pro-inflammatory cytokines,
and once they enter the brain, they cannot only directly injure
dopaminergic neurons, they can also activate resident microglia
and astrocytes to indirectly contribute to cell loss. Indeed, CD4+
T-leukocytes have been implicated in MPTP induced DA cell
death [31] and increased neutrophil infiltration has been
associated with selective nigral dopaminergic degeneration in PD
Figure 3. Changes in albumin extravasation following intrastriatal 6-OHDA lesions. Compared to sham animals (A), vehicle (B) and SP (C)
treated animals demonstrate albumin immunoreactivity in the ipsilateral SN at day 21, whereas both NAT (D) and L-733,060 (E) treated animals
resemble shams. Color deconvolution (F) confirms these trends. Arrows denote albumin. Bar=500 mm.
doi:10.1371/journal.pone.0034138.g003
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NK1 antagonist reduced levels of inflammation including a
decrease in ED-1 immunoreactivity detected CD68 protein, a
marker of both resident phagocytotic microglia and peripheral
blood-borne macrophages [33]. We suggest that the early increase
in SP content within the nigra may induce neurogenic inflamma-
tion and thus facilitate BBB breakdown and subsequent dopami-
nergic neuronal loss. This agrees with the reported actions of SP,
which induces and augments many aspects of the inflammatory
response including leukocyte activation, endothelial cell adhesion
molecule expression and cytokine production.
Inflammatory processes are important mediators of 6-OHDA-
induced cell death [34,35]. Under normal conditions, the SN
contains a large number of microglia as dopaminergic neurons are
in a state of constant oxidative stress due to the production of ROS
during DA metabolism [36]. Indeed, we found Iba-1 immunore-
active microglia were present within the SN of sham animals.
Although microglia are vital to the control of immune and
homeostatic functions within the brain, once activated they
produce inflammatory cytokines such as IL-1, IL-6, and TNF-a,
glutamate and quinolinic acid, superoxide radicals and NO [37].
A major source of ROS is microglial NADPH oxidase. In PD,
both NADPH oxidase and ROS production are upregulated due
to increased microglial activation [5]. ROS may cause apoptosis of
neurons by inducing mitochondrial dysfunction and damaging
lipids, proteins and DNA [38]. Indeed, ROS are thought to be
major contributors to 6-OHDA-mediated cell death [39]. Notably,
microglia express NK1 receptors and SP is considered to be a
potent microglial activator [40,41,42].
In the current study, an increase in Iba-1 positive microglia was
observed prior to TH neuronal loss, confirming that the
appearance of activated microglia may proceed neurodegenera-
tion [43]. Moreover, activation of microglia correlated with the
degree of dopaminergic degeneration, as SP treated animals had
both the greatest loss of DA neurons and the most nigral Iba-1 and
ED-1 immunoreactive microglia. Conversely, animals treated with
the NK1 antagonists had less Iba-1 immunoreactive microglia and
a small reduction in the number of ED-1 positive microglia. Thus,
inhibition of microglial activation using the SP, NK1 receptor
antagonists may have contributed to the protection of dopami-
nergic neurons.
Astrocytes also express the NK1 receptor [44], and once
activated by SP, NF-kb translocates to the nucleus resulting in
cytokine secretion [45]. An increase in GFAP positive reactive
astrocytes was observed in the SN of all 6-OHDA groups.
Reactive astrocytes may be beneficial by metabolizing excess
cytosolic DA and through secretion of glial- and brain-derived
neurotrophic factors and antioxidant enzymes [46]. Conversely,
their secretion of pro-inflammatory cytokines may contribute to
inflammatory processes and injury. In the current study, the effect
astrocytes had on dopaminergic neurons is unclear as both SP and
NK1 antagonist treated animals had a reduction in the number of
these cells compared to vehicle treated animals. Nonetheless, due
to SP’s ability to induce proinflammatory cytokine secretion from
astrocytes, we suggest that the reduction in reactive astrocytes by
NK1 antagonists was beneficial and contributed to the preserva-
tion of dopaminergic neurons.
NK1 antagonism may also both directly reduce excitotoxic
damage to DA terminals and neurons, or indirectly reduce
excitotoxic damage by protecting dopaminergic neurons through
other means and thus reduce subsequent subthalamic nucleus
(STN) overactivity. Due to the functional arrangement of the BG,
decreased striatal DA causesoveractivity ofthe STN. The STNuses
glutamate to send excitatory signals to the GP and SN to modulate
the burst firing of dopamine neurons [47]. With no inhibition of the
STN, excess glutamate will be released within the SN to bind to
glutamate receptors located on dopaminergic neurons causing
excitotoxic damage, a major contributor of cell death in PD [48].
Moreover, NMDA-evoked striatal glutamate release requires the
activation of striatal NK1 and DA receptors [49].
In conclusion, SP is increased in the intrastriatal 6-OHDA
model of early PD. This elevation in SP levels may contribute to
the demise of dopaminergic neurons by modulating CNS
inflammatory processes including the activation of microglia and
astrocytes, as well as facilitating increased DA turnover and free
radical production. This is the first study to implicate SP induced
neurogenic inflammation in BBB breakdown and dopaminergic
cell death in experimental early PD. Thus, NK1 antagonists may
represent a novel therapeutic agent that may slow down
progression of PD and prevent functional deficits in early PD.
Materials and Methods
Ethics Statement
All experimental protocols were conducted according to the
guidelines established by the National Health and Medical
Research Council of Australia and were approved by the animal
ethics committees of the University of Adelaide and SA Pathology
(approval number 65/05).
Figure 4. The effects of SP and NK1 antagonist treatment on
neuroinflammation. Number of reactive (Iba-1 immunoreactive)/
activated (ED-1 immunoreactive) microglia (A), and reactive astrocytes
(B) in the ipsilateral SN following 6-OHDA intrastriatal lesions.
doi:10.1371/journal.pone.0034138.g004
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A total of 75 male, Sprague-Dawley rats weighing 250–300 g
were group housed under a 12-hour light/dark cycle with access to
food and water ad libitum. Animals were randomly assigned to
sham (not lesioned) or 6-OHDA lesioning plus treatment with
either an NK1 receptor antagonist (N-acetyl-L-tryptophan; NAT
or L-733,060), SP, treatment vehicle (artificial CSF) or no
treatment. The NK1 antagonist treated groups were administered
either 2 mL of 50 nM NAT (Sigma) or 2 mL of 100 nM L-733,060
(Tocris) into the right lateral ventricle (stereotaxic co-ordinates:
AP: 20.6 mm, ML: 1.5 mm relative to bregma and V: 3.5 mm
from dura [50]) immediately following intrastriatal 6-hydroxydo-
pamine-bromide (6-OHDA; Sigma) injections. The SP treated
group was administered 2 mL of SP salt-acetate (5 mg/mL; Sigma)
as described above for the NK1 antagonist groups. The NK1
receptor antagonist and SP doses were chosen on the basis of their
known physiological effects in the nigra [51,52]. The vehicle
treated group received equal volume of vehicle (artificial CSF).
Shams underwent the surgical procedure only without adminis-
tration of the 6-OHDA.
The intrastriatal, 6-OHDA model of early PD has been
previously described in detail elsewhere [53]. Briefly, animals
were anesthetized with 3% Isoflurane (1.5 L/min O2), placed onto
a stereotaxic device and two 0.7 mm burr holes then made over
the right striatum at stereotaxic coordinates (1) AP: 0.5 mm, ML:
2.5 mm, and (2) AP: 20.5 mm, ML: 4.2 mm relative to bregma
[50,53]. Two mL of 6-OHDA (5 mg/mL) was then injected into the
right striatum at 5.0 mm ventral from the dura in each of the two
burr holes at a rate of 0.5 mL/min, with the needle then left in
place for 2 min before being slowly retracted. Body temperature
was maintained with a thermostatically controlled heating pad
throughout the surgical procedures.
Motor Outcome
Following induction of PD, animals were assessed for motor
deficits on an accelerating rotarod. The rotarod is a sensitive test of
motor deficits by testing general motor function including co-
ordination and balance, and tests sensorimotor learning deficits in
early stage PD [54]. The rotarod task has been described in detail
elsewhere [55]. In this study, animals were not pre-trained but
were tested at the same time each morning on days 3, 7, 10, 14, 17
and 21 post-lesion.
Assessment of substance P, blood brain barrier and
inflammation using immunohistochemistry
Following a predetermined survival period, animals were
anesthetized with 5% Isoflurane, venously administered Heparin
(5000 IU/mL) and transcardially perfused with 10% buffered
formalin. The brain was cut into consecutive 2 mm coronal slices,
processed and embedded in paraffin. The level containing the SN
was cut into serial 5 mm sections that were processed as follows.
Dopaminergic neurons were observed with tyrosine hydroxylase
(TH) immunoreactivity (Chemicon; 1:8000; citrate retrieval).
Nigral SP protein content was determined using SP immunore-
activity (Santa Cruz; 1:2000; EDTA retrieval). Iba-1 immunore-
activity (Wako; 1:5000; citrate retrieval) and ED-1 immunoreac-
tivity (AbD Serotec; 1:400; citrate retrieval) was used to assess
reactive and activated microglia. GFAP immunoreactivity (Dako;
Figure 5. The effects of SP and NK1 antagonist treatment on Iba-1, ED-1 and GFAP immunoreactivty in the ipsilateral SN following
intrastriatal 6-OHDA lesions at day 21. Arrows denote specified immunoreactivity. Bar=400 mm.
doi:10.1371/journal.pone.0034138.g005
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breakdown was observed using albumin immunoreactivity (Coo-
per Biomedical; 1:20000; no retrieval).
All sections underwent a similar immunohistochemical proce-
dure, with all antibodies incubated at room temperature and PBS
washes applied between each antibody. Briefly, sections were de-
waxed, dehydrated and placed in methanol with 30% hydrogen
peroxide. Specified microwave antigen retrieval was performed as
required and sections incubated for 45 min in 3% normal horse
serum. Primary antibody was added overnight before specific
biotinylated secondary antibody (Vector,1:250) was added for
30 mins. Tertiary streptavidin peroxidase conjugate (SPC; Pierce,
1:1000) was added for 1 hour and the immunocomplex visualised
using 3,39diaminobenzidine (DAB; Sigma) as a chromogen in the
peroxidase reaction.
TH immunoreactive neurons were counted in the ipsilateral
and contralateral SN at 206 magnification. The number of
ipsilateral TH positive neurons was compared to contralateral
neurons (internal control) to determine the percentage of
ipsilateral dopaminergic cell loss. Iba-1 positive microglia, with
intense cytoplasmic immunoreactivity and shortened processes,
along with ED-1 immunoreactive microglia were counted in the
ipsilateral SN at 206magnification. The area of the SN was also
determined to allow the number of reactive/activated microglia
per mm
2 to be determined. The number of reactive astrocytes was
assessed in a similar manner to microglia with astrocytes counted
that had upregulated GFAP immunoreactivty and shortened
processes.
To non-subjectively estimate SP protein content and BBB
integrity within the ipsilateral SN, all immunohistochemistry was
subject to automated, color deconvolution analysis [54]. Briefly,
SP and albumin immmunohistochemical sections were scanned
using a Nanozoomer (Hamamatsu) before jpeg images at 206
magnification for SP and 106 magnification for albumin were
exported from both the ipsilateral and contralateral SN. These
jpeg images underwent color deconvolution, which separates the
DAB color vector image from the hematoxylin color vector image.
The amount of DAB precipitate (antigen content) was estimated
using the histogram analysis of the DAB color image and a
mathematical formula, which determined the percentage of
weighted DAB (DABwt%) in the image. The weighting of the
DAB is critical as it eliminates non-specific background staining
whilst amplifying positive staining, and also gives a semi-
quantitative estimate of intensity upon which statistical analyses
can be performed [56]. As SP immunoreactivity can differ from
batch to batch due to minor technical variations, each image was
corrected using an internal control (interhemispheric leptome-
niges), which is affected only by technique and not induction of
PD. This allows an accurate assessment of the amount of SP
content in the SN. Albumin immunoreactivity is unaffected
between batches, however the amount of adjusted DABwt%
within the ipsilateral SN was compared to contralateral SN
(internal control).
Semi-quantification of substance P using ELISA
At day 3 or 7 following intrastriatal 6-OHDA lesions, animals
were re-anaesthetized with 5% Isoflurane (1.5 L/min 02),
decapitated and their brain removed. The striatum and midbrain
were rapidly dissected out, the hemispheres divided and the cortex
removed from the surrounding structures. Each brain region was
weighed then homogenised in buffer containing 0.01% TritonX-
100, DL-dithioreitol and protease inhibitors pepstatin A, aproti-
nin, leupeptin and phenylmethanesulfonyl fluoride. Protein
content of the samples was estimated using a Biorad protein
estimation assay, with samples diluted with tris-buffered saline
(TBS) to 400 ng protein per 100 ml sample. An ELISA assay was
used to determine the level of SP in the striatum and SN. Brain
homogenate samples and control blank wells were loaded in
triplicate and left overnight at 4uC. Blocking agent was added for
1 hour before 100 mL of SP primary antibody (Chemicon; 1:1000)
was incubated at 37uC for at least 1 hr. 100 mL of secondary anti-
rabbit horseradish peroxidase conjugate (Rockford, 1:500) anti-
body was incubated for 1 hr at 37uC before 100 mL/well of liquid
substrate system 3,39-5,59-tetramethylbenzidine (Sigma) used to
visualize SP content. TBS washes (36) occurred between each
step.
Statistical Analysis
All data was analysed using an Analysis of Variance (ANOVA)
followed by Neuman-Keuls multiple comparison posthoc tests
(GraphPad Prism). Data is expressed as mean 6 standard error of
the mean (SEM).
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